Trial Profile
Nucleos(t)ide withdrawal in HBeAg negative hepatitis B virus infection to promote HBsAg clearance. (NUC-B)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 23 Feb 2017
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- 23 Feb 2017 New trial record